.Pharmacolibrary.Drugs.C_CardiovascularSystem.C08C_SelectiveCalciumChannelBlockersWithMainlyVascula.C08CA16_Clevidipine.Clevidipine

Information

Clevidipine is an ultrashort-acting dihydropyridine calcium channel blocker used for the rapid reduction of blood pressure in cases of acute hypertension. It is administered intravenously and is approved for use in clinical settings such as perioperative hypertension and hypertensive emergencies.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects following intravenous infusion.

References

1. Ericsson, H, et al., & Regårdh, CG (2001). Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. Chirality 13(3) 130–134. DOI:10.1002/1520-636X(2001)13:3<130::AID-CHIR1009>3.0.CO;2-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11270321

2. Zuleta-Alarcón, A, et al., & Bergese, S (2014). [The role of clevidipine in hypertension management: clinical results]. Revista espanola de anestesiologia y reanimacion 61(10) 557–564. DOI:10.1016/j.redar.2014.06.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25236947

3. Ericsson, H, et al., & Regårdh, CG (1999). Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug metabolism and disposition: the biological fate of chemicals 27(5) 558–564. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10220482

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)